## Hao Xie

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7008454/publications.pdf

Version: 2024-02-01

687220 610775 34 611 13 24 citations h-index g-index papers 35 35 35 1159 citing authors all docs docs citations times ranked

| #  | Article   | IF  | Citations |
|----|---|-----|-----------|
| 1  | Gastroesophageal reflux disease and paraneoplastic neurological syndrome associated with<br><scp>longâ€term</scp> survival in limited stage <scp>smallâ€cell</scp> lung cancer. Thoracic Cancer,<br>2022, 13, 925-933.  | 0.8 | 2         |
| 2  | Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology, 2021, 23, 112-121.   | 0.6 | 53        |
| 3  | The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. Annals of Surgical Oncology, 2021, 28, 1845-1858.   | 0.7 | 5         |
| 4  | Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clinical Cancer Research, 2021, 27, 141-149.  | 3.2 | 17        |
| 5  | The diagnosis and outcome of Krukenberg tumors. Journal of Gastrointestinal Oncology, 2021, 12, 226-236.  | 0.6 | 6         |
| 6  | The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 234-245.  | 1.2 | 9         |
| 7  | Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer, 2020, 126, 26-36.   | 2.0 | 82        |
| 8  | Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Oncologist, 2020, 25, e1681-e1690.  | 1.9 | 5         |
| 9  | Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 586-590.  | 0.6 | 5         |
| 10 | Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. Oncologist, 2020, 25, 810-817.  | 1.9 | 11        |
| 11 | Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091091. | 1.4 | 12        |
| 12 | Safety of Influenza Vaccine in Patients With Cancer Receiving Pembrolizumab. JCO Oncology Practice, 2020, 16, e573-e580.  | 1.4 | 37        |
| 13 | Ki-67 Labeling Index in Pulmonary Carcinoid Tumors: Comparison Between Small Biopsy and Resection<br>Using Tumor Tracing and Hot Spot Methods. Archives of Pathology and Laboratory Medicine, 2020, 144,<br>982-990.  | 1.2 | 10        |
| 14 | Reply to On the proportion of male breast cancer among all breast cancers. Cancer, 2020, 126, 2034-2035.  | 2.0 | 1         |
| 15 | Validation of American Joint Committee on Cancer 8 <sup>th</sup> edition of TNM staging in resected distal pancreatic cancer. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2020, 11, 25-39.   | 0.6 | 5         |
| 16 | Adjuvant Therapy in High-Risk Renal Cell Cancer: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2019, 94, 1524-1534.   | 1.4 | 7         |
| 17 | Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Lung Cancer, 2019, 135, 73-79.   | 0.9 | 16        |
| 18 | Two Cases of Krukenberg Tumors from ALK-Rearranged Lung Adenocarcinoma: An Uncommon Site of Metastasis. Journal of Thoracic Oncology, 2019, 14, e229-e230.  | 0.5 | 0         |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Investigational New Drugs, 2019, 37, 755-762.                              | 1.2 | 18        |
| 20 | Recent Advances in the Clinical Targeting of Hedgehog/GLI Signaling in Cancer. Cells, 2019, 8, 394.   | 1.8 | 59        |
| 21 | Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: AÂpropensity score matched analysis.<br>European Journal of Surgical Oncology, 2019, 45, 1432-1438.   | 0.5 | 63        |
| 22 | A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 184-189.    | 0.6 | 20        |
| 23 | Colorectal Serrated Polyp With Stromal Changes: An Interobserver Agreement Study.<br>Gastroenterology Research, 2019, 12, 299-304.  | 0.4 | 1         |
| 24 | The Management of Older Adults with Pancreatic Adenocarcinoma. Geriatrics (Switzerland), 2018, 3, 85.   | 0.6 | 4         |
| 25 | The prognostic significance of ATRX in pulmonary carcinoid tumors Journal of Clinical Oncology, 2018, 36, e20543-e20543.  | 0.8 | 0         |
| 26 | The Cleveland Clinic Experience With Primary Central Nervous System Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 140-146.   | 0.6 | 6         |
| 27 | Diagnostic utility of TP53 and cytokeratin 7 immunohistochemistry in idiopathic inflammatory bowel disease-associated neoplasia. Modern Pathology, 2014, 27, 303-313.   | 2.9 | 55        |
| 28 | Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer, 2013, 119, 173-181.   | 2.0 | 28        |
| 29 | High Expression of Survivin Is Prognostic of Shorter Survival but Not Predictive of Adjuvant Gemcitabine Benefit in Patients with Resected Pancreatic Adenocarcinoma. Journal of Histochemistry and Cytochemistry, 2013, 61, 148-155. | 1.3 | 9         |
| 30 | Primary central nervous system lymphoma in the elderly: the Cleveland clinic experience. Anticancer Research, 2013, 33, 3251-8.   | 0.5 | 6         |
| 31 | Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2012, 5, 347-55.   | 0.5 | 3         |
| 32 | The Catalytic Asymmetric Dielsâ€"Alder Reactions and Postâ€cycloaddition Reductive Transpositions of 1â€Hydrazinodienes. Chemistry - A European Journal, 2011, 17, 11131-11134.   | 1.7 | 16        |
| 33 | Design, Synthesis, and Reactivity of 1-Hydrazinodienes for Use in Organic Synthesis Chemlnform, 2005, 36, no.   | 0.1 | 0         |
| 34 | Design, Synthesis, and Reactivity of 1-Hydrazinodienes for Use in Organic Synthesis. Journal of the American Chemical Society, 2005, 127, 8612-8613.  | 6.6 | 40        |